Lobo Eunice, Shah Shimoni, Rangan Sheela, Dholakia Yatin, Mistry Nerges
The Foundation for Medical Research, Mumbai, 400018, India.
Gates Open Res. 2018 May 10;2:9. doi: 10.12688/gatesopenres.12785.2. eCollection 2018.
Mumbai is witnessing a rising incidence of all forms of drug resistant tuberculosis (DR-TB). A population-based, retrospective study was conducted between April and July 2014, in 15 high TB burden wards in Mumbai, to capture the patient pathways to TB care. A total of 23 DR-TB patients were identified and their pathways to access DR-TB care were recorded using semi-structured interviews. The total DR-TB pathway time of new patients (who did not report any past episode of TB) (180 days; IQR 123,346) was found to be more than twice that of retreatment patients (who reported a past episode of TB) (69 days; IQR 42,128). The unacceptable delay for diagnosis and treatment of DR-TB in Mumbai advocates for consistent implementation of early screening of patients using rapid gene-based technologies.
孟买各种形式的耐药结核病（DR-TB）发病率正在上升。2014年4月至7月间，在孟买15个结核病负担较重的病房开展了一项基于人群的回顾性研究，以了解结核病治疗的患者路径。共识别出23例耐药结核病患者，并通过半结构化访谈记录了他们获得耐药结核病治疗的路径。新患者（未报告过去有任何结核病发作史）的耐药结核病总路径时间为180天（四分位距123,346），是复治患者（报告过去有结核病发作史）的两倍多（69天；四分位距42,128）。孟买耐药结核病诊断和治疗的不可接受的延迟情况，提倡持续采用基于快速基因技术对患者进行早期筛查。
